Abstract
In the last few years, the fields of Medicinal Chemistry and especially the ones related to the so-called Personalized Medicine, have received a great attention. Significant investment and remarkable researches surround the matter; however, not all those promising advances are reaching patients as quickly as they should. The absence of an adequate regulatory framework could be of no help. The complete and/or massive sequencing of individual genomes faces many ethical-legal challenges. Some of them are access to Personalized Medicine; the treatment of a large volume of sensitive information and the use of tools produced by "big data" systems in clinical care or in predictive models. In addition, the legal protection of personal data related to health, the exercise of autonomy by patients, closely related to the regulation regarding clinical trials, are seriously involved. Our purpose of this work is to review the regulations of the European Union, in an attempt to contribute to a better understanding of the legal framework for the implementation and development of health systems based on Personalized Medicine.
Keywords: Personalized medicine, Medicinal chemistry, Legal issues, Genomics, Data protection, Clinical trials.
Current Topics in Medicinal Chemistry
Title:Personalized Medicine and Medicinal Chemistry: Toward a Legal Framework in the European Union
Volume: 18 Issue: 25
Author(s): Aliuska Duardo-Sánchez*Iñigo De Miguel Beriain
Affiliation:
- Department of Public Law, Chair in Law and Human Genome Research Group, University of the Basque Country UPV/EHU, 48940, Leioa, Biscay,Spain
Keywords: Personalized medicine, Medicinal chemistry, Legal issues, Genomics, Data protection, Clinical trials.
Abstract: In the last few years, the fields of Medicinal Chemistry and especially the ones related to the so-called Personalized Medicine, have received a great attention. Significant investment and remarkable researches surround the matter; however, not all those promising advances are reaching patients as quickly as they should. The absence of an adequate regulatory framework could be of no help. The complete and/or massive sequencing of individual genomes faces many ethical-legal challenges. Some of them are access to Personalized Medicine; the treatment of a large volume of sensitive information and the use of tools produced by "big data" systems in clinical care or in predictive models. In addition, the legal protection of personal data related to health, the exercise of autonomy by patients, closely related to the regulation regarding clinical trials, are seriously involved. Our purpose of this work is to review the regulations of the European Union, in an attempt to contribute to a better understanding of the legal framework for the implementation and development of health systems based on Personalized Medicine.
Export Options
About this article
Cite this article as:
Duardo-Sánchez Aliuska *, De Miguel Beriain Iñigo , Personalized Medicine and Medicinal Chemistry: Toward a Legal Framework in the European Union, Current Topics in Medicinal Chemistry 2018; 18 (25) . https://dx.doi.org/10.2174/1568026619666181120144213
DOI https://dx.doi.org/10.2174/1568026619666181120144213 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemoprevention Strategies for High Risk Women
Current Women`s Health Reviews Pinocembrin-Enriched Fractions of Elytranthe parasitica (L.) Danser Modulates Apoptotic and MAPK Cellular Signaling in HepG2 Cells
Anti-Cancer Agents in Medicinal Chemistry Biomarker Discovery and Translation in Metabolomics
Current Metabolomics A Proposed Screening Paradigm for Discovery of Covalent Inhibitor Drugs
Drug Metabolism Letters Computer-Aided Drug Design for AMP-Activated Protein Kinase Activators
Current Computer-Aided Drug Design Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Advances in Methods for Predicting Phase I Metabolism of Polyphenols
Current Drug Metabolism Structure-Function Relationships of Plasminogen Activator Inhibitor-1 and Its Potential as a Therapeutic Agent
Current Drug Targets Significant Association of miR-605 rs2043556 with Susceptibility to Breast Cancer
MicroRNA Editorial [Hot Topic: MicroRNA Regulation and its Biological Significance in Personalized Medicine and Aging (Guest Editor: Eugenia Wang)]
Current Genomics Gene Therapy for Primary Immunodeficiency Diseases: Recent Progress and Misgivings
Current Pharmaceutical Design Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry Actinomycetes as a Paramount Source of Biologically Important Enzyme Inhibitors – “A Boon to Mankind”
Current Bioactive Compounds Electroporation Advances in Large Animals
Current Gene Therapy Targeting the Cell Cycle in the Pursuit of Novel Chemotherapies Against Parasitic Protozoa
Current Pharmaceutical Design Patent Selections:
Recent Patents on Nanotechnology Increasing Sensitivity to Radiotherapy and Chemotherapy by Using Novel Biological Agents that Alter the Tumor Microenvironment
Current Molecular Medicine Anticancer Evaluation of 3,4,5,4'-trans-tetramethoxystilbene (DMU-212) and Its Analogs Against an Extensive Panel of Human Tumor Cell Lines
Letters in Drug Design & Discovery The Centrosome: A Target for Cancer Therapy
Current Cancer Drug Targets Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry